实盘配资

专注给予质高价优

科学论文

Poster #41: A phase 2 study of HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy as firstline therapy in advanced or recurrent squamous non-small cell lung cancer
ASCO 2025
A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors
ASCO 2025
Serplulimab versus placebo plus chemotherapy as first line treatment for extensive stage small cell lung cancer: efficacy and safety from the end of study analysis of the international phase 3 ASTRUM 005 study
ASCO 2025
A randomized, double-blind, international phase 3 trial comparing HLX22 in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy with or without pembrolizumab for first-line treatment for HER2-positive locally advanced or metastatic G/GEJC
ASCO 2025
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced/Metastatic Solid Tumors
ASCO 2025
Poster #294: Safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of HLX301, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors
ASCO 2025

知识产权

专利申请数量	PCT申请数量	国内外授权专利数量	注册司法权区	申请日期	到期日	发明专利数量
809	90	134	中国大陆	2011-03-18	2031-03-18	97